WaferGen Bio Financial Ratios

WaferGen Bio systems Inc -- USA Stock  

USD 6.9  0.00  0.00%

Please harness WaferGen Bio systems fundamental data analysis to find out if markets are presently mispricing the firm. We found thirty-one available indicators for WaferGen Bio systems which can be compared to its rivals. To make sure the equity is not overpriced, please check out all WaferGen Bio systems fundamentals including its Price to Book, Cash Flow from Operations, Z Score, as well as the relationship between Cash and Equivalents and Total Asset . Given that WaferGen Bio systems has Number of Shares Shorted of 240.41 K, we strongly advise you confirm WaferGen Bio systems prevalent market performance to make sure the company can sustain itself down the road.Use WaferGen Bio to protect against small markets fluctuations. The stock experiences normal downward trend, but the immediate impact on correlations cannot be determined at the moment . Check odds of WaferGen Bio to be traded at $6.83 in 30 days

WaferGen Bio Company Summary

WaferGen Bio competes with Agilent Technologies, Ingersoll Rand, Sensata Technologies, Visualant, and ELECTRO SENSORS. It offers SmartChip RealTime polymerase chain reaction system which offer a suite of gene expression and genome analysis technologies enabling biomarker discovery and validation on a single platform with the sensitivity and accuracy of PCR. WaferGen Biosystems Incs SmartChip RealTime PCR system consists of two instrumentation components comprising a SmartChip MultiSample NanoDispenser for applying sample assay and reaction mix to the SmartChip Panels and a SmartChip Cycler for thermal cycling and collecting data from the realtime PCR assays. It also offer SmartChip SingleCell Isolation System which isolates thousands of single cells and processes specific cells for analysis SmartChip Target Enrichment system that amplifies the targets of interest through PCR and Apollo 324TM library preparation System a walkaway automation platform that offers DNA RNASeq and ChIPSeq library preparation kits for analysis on NGS platforms. WaferGen Biosystems Inc focuses on providing its solutions to researchers who perform genetic analysis and cell biology primarily at pharmaceutical and biotech companies academic and private research centers and diagnostics companies involved in biomarker research. WaferGen Biosystems Inc. was founded in 2002 and is headquartered in Fremont California.

WaferGen Bio Profit Margin vs Shares Outstanding

WaferGen Bio systems Inc is rated second in profit margin category among related companies. It is rated first in shares outstanding category among related companies .

WaferGen Bio Fundamentals

 Better Than Average     
 Worse Than Average Compare WaferGen Bio to competition
FundamentalsWaferGen BioPeer Average
Return On Asset(90.11) % (15.64) %
Profit Margin(175.04) % (5.5) %
Operating Margin(171.93) % (10.91) %
Current Valuation16.04 M152.14 B
Shares Outstanding3.8 M1.43 B
Shares Owned by Insiders19.5 % 6.91 %
Shares Owned by Institutions5.8 % 18.37 %
Number of Shares Shorted240.41 K3.24 M
Price to Earning(1.16) times40.69 times
Price to Book12.86 times14.44 times
Price to Sales1.99 times17.81 times
Revenue9.24 M9.85 B
Gross Profit3.95 M21.75 B
Net Income(20.85 M)517.71 M
Cash and Equivalents5.15 M3.89 B
Cash per Share1.36 times5.17 times
Total Debt2.94 M7.36 B
Debt to Equity0.8 times0.72 times
Current Ratio1.82 times3.3 times
Cash Flow from Operations(13.54 M)1.25 B
Earnings Per Share(5.93) times2.3 times
Number of Employees5510.67 K
Market Capitalization26.22 M29.78 B
Total Asset11.39 M126.86 B
Retained Earnings(119.81 M)38.24 B
Working Capital3.9 M3.58 B
Current Asset8.68 M36.8 B
Current Liabilities4.77 M33.34 B
Z Score-9.2708.73
< 91% 

Chance of Financial Distress

WaferGen Bio systems Inc has more than 91 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info


Compare WaferGen Bio To Peers
Rolland Carlson CEO and President and Director, Ph.D
Ivan Trifunovich Executive Chairman, Ph.D
More Executives

Opportunity Range

October 18, 2017 Opportunity Range